Voyager Therapeutics Inc.

NASDAQ: VYGR · Real-Time Price · USD
3.73
0.01 (0.27%)
At close: Aug 15, 2025, 3:59 PM
3.77
0.83%
After-hours: Aug 15, 2025, 07:35 PM EDT

Voyager Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
5.2M 6.47M 6.28M 24.63M 29.58M 19.52M 90.06M 4.61M 4.85M 150.48M -41.09M 41.09M 712K 658K 28.07M 1.48M 1.36M 6.5M
Cost of Revenue
n/a n/a n/a n/a 34.45M 1.2M 1.33M 945K 1.09M 18.57M 834K 1.34M 1.2M 2.81M 14.02M 17.91M 19.5M 22.35M
Gross Profit
5.2M 6.47M 6.28M 24.63M -4.87M 18.32M 88.73M 3.67M 3.77M 131.91M -41.92M 39.74M -492K -2.15M 14.05M -16.43M -18.15M -15.85M
Operating Income
-36.63M -34.69M -38.3M -13.78M -15.03M -16.18M 54.06M -29.51M -25.43M 122.88M -24.56M 14.44M -19.37M -21.35M 5.7M -25.15M -28.59M -25.59M
Interest Income
2.83M 3.29M n/a 4.58M 4.89M 4.87M 3.15M 3.43M 3.27M 1.86M 976K 545K 219K 31K n/a 121K 48K 19K
Pretax Income
-33.37M -30.98M -33.9M -9M -10.12M -11.32M 57.22M -26.08M -22.15M 124.75M -23.61M 17.62M -19.09M -21.32M 5.71M -25.14M -30.12M -21.65M
Net Income
-33.38M -31.02M -34.49M -9.04M -10.14M -11.33M 56.4M -25.9M -22.21M 124.04M -23.63M 17.62M -18.87M -21.29M 5.71M -25.14M -30.12M -21.65M
Selling & General & Admin
10.49M 9.64M 8.99M 8.17M 10.15M 8.61M 10.24M 8.26M 8.29M 9.03M 8.46M 7.31M 7.55M 7.66M 8.35M 8.71M 10.44M 9.74M
Research & Development
31.33M 31.53M 35.58M 30.24M 34.45M 25.9M 24.42M 25.86M 21.98M 18.57M 14.55M 19.34M 12.53M 14.35M 14.02M 17.91M 19.5M 22.35M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a 3K n/a 953K 2.64M 61K n/a 6K -112K -1.58M 3.92M
Operating Expenses
41.83M 41.17M 44.58M 38.41M 44.6M 34.5M 34.66M 34.12M 30.28M 27.6M 23.01M 26.64M 20.08M 22.01M 22.37M 26.63M 29.94M 32.09M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 997K n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
41.83M 41.17M 44.58M 38.41M 44.6M 35.7M 36M 34.12M 30.28M 27.6M 23.01M 26.64M 20.08M 22.01M 22.37M 26.63M 29.94M 32.09M
Income Tax Expense
15K 37K 584K 43K 24K 14K 822K -177K 59K 704K 16K n/a -219K -31K -1.48M -121K -48K -19K
Shares Outstanding (Basic)
58.67M 58.35M 57.97M 57.85M 57.72M 57.12M 43.98M 43.86M 43.52M 40.63M 38.55M 38.51M 38.17M 38.05M 37.8M 37.52M 37.58M 37.33M
Shares Outstanding (Diluted)
58.67M 58.35M 57.97M 57.85M 57.72M 57.12M 45.08M 43.86M 43.52M 42.16M 38.55M 39.57M 38.3M 38.05M 37.8M 37.78M 37.58M 37.5M
EPS (Basic)
-0.57 -0.53 -0.59 -0.16 -0.18 -0.2 1.28 -0.59 -0.51 3.05 -0.61 0.46 -0.49 -0.56 0.15 -0.67 -0.8 -0.58
EPS (Diluted)
-0.57 -0.53 -0.59 -0.16 -0.18 -0.2 1.25 -0.59 -0.51 2.94 -0.61 0.45 -0.49 -0.56 0.15 -0.67 -0.8 -0.58
EBITDA
-35.56M -33.68M -37.29M -12.65M -13.63M -14.99M 55.4M -28.56M -24.34M 123.96M -23.73M 15.78M -18.16M -18.54M 7.18M -23.92M -27.4M -24.32M
EBIT
-36.63M -34.69M -38.3M -13.78M -15.03M -16.18M 57.22M -29.51M -25.43M 122.88M -24.56M 17.62M -19.37M -21.35M 5.7M -25.15M -28.59M -25.59M
Depreciation & Amortization
1.06M 1.01M 1.01M 1.13M 1.39M 1.2M 1.33M 945K 1.09M 1.07M 834K 1.34M 1.2M 2.81M 1.48M 1.22M 1.19M 1.27M